Legend Biotech Names CEO, CFO Huang to the Board of Directors
30 December 2021 - - Dr. Ying Huang, US-based clinical-stage biotechnology company Legend Biotech Corp's (NASDAQ: LEGN) chief executive officer and chief financial officer, has been appointed as a director to the company's board of directors, the company said.

Dr. Huang will serve as a Class I director.

Ying Huang, Ph.D., has served as Legend Biotech's chief executive officer since September 2020 and as its chief financial officer since July 2019.

Prior to joining Legend Biotech, Dr. Huang was a Managing director and Head of Biotech Equity Research at BofA Securities, Inc. from August 2014 to July 2019, where he led a team of analysts covering more than 30 biotechnology companies including Amgen, Gilead, Celgene, Biogen and others that encompass a wide range of therapeutic areas.

Dr. Huang became a biotechnology analyst in 2007 and worked at Wells Fargo (formerly Wachovia), Credit Suisse, Gleacher and Barclays before joining BofA Securities, Inc.

Prior to his Wall Street career, Dr. Huang was a Principal Scientist at Schering-Plough (now Merck and Co.) in the Department of Chemical Research focusing on small molecule drug discovery in the therapeutic areas of cardiovascular and central nervous system.

He is also the co-author of multiple patents and peer-reviewed publications. Dr. Huang holds a Ph.D. in Bio-organic Chemistry from Columbia University.

Dr. Huang also studied at Columbia Business School and in the Special Class for the Gifted Young at the University of Science and Technology of China.

Legend Biotech is currently engaged in a strategic collaboration to develop and commercialize its lead product candidate, ciltacabtagene autoleucel (cilta-cel), an investigational BCMA-targeted CAR-T cell therapy for patients living with multiple myeloma.